The European Commission has granted marketing authorization for Moderna's mRNA-1083 vaccine — branded mCOMBRIAX — making it the world's first approved combination shot protecting against both influenza and COVID-19 in a single dose. The approval, announced this week, marks a significant milestone for mRNA vaccine technology, though the shot has yet to receive authorization in the United States, where it was developed.
Moderna's combination respiratory vaccine has cleared a major regulatory hurdle in Europe, receiving full marketing authorization from the European Commission following a positive assessment by the European Medicines Agency's (EMA) scientific committee in February 2026.
The vaccine, known scientifically as mRNA-1083 and commercially as mCOMBRIAX, uses messenger RNA technology — the same platform that underpinned Moderna's successful COVID-19 vaccine — to simultaneously prime the immune system against both seasonal influenza and COVID-19. It is intended primarily for adults, with a particular focus on those at high risk from serious respiratory illness.
Moderna CEO Stéphane Bancel welcomed the European decision. "By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk," Bancel said in a company press release. "mCOMBRIAX offers an important new option for Europeans, while also aiming to strengthen the resilience of healthcare systems across Europe."
The authorization is a notable commercial and scientific victory for Moderna, which has sought to expand and diversify its mRNA product pipeline beyond COVID-19 vaccines. Combination vaccines are broadly seen as a practical solution to the challenge of encouraging uptake among adults who already face multiple recommended annual shots, including separate flu and COVID boosters.
However, the drug remains unavailable in the United States despite being developed there. The US Food and Drug Administration has not yet authorized mCOMBRIAX, and Moderna has not publicly disclosed a timeline for when American regulators might act on the application. The gap between US and European approval timelines has attracted attention given the current climate around US regulatory agencies, including ongoing uncertainty about vaccine policy direction at federal health bodies.
The situation echoes a broader pattern in which US-developed pharmaceutical products sometimes reach foreign markets ahead of receiving domestic clearance, often due to differing regulatory processes, timelines, or political environments rather than differences in the underlying science.
With authorization secured in Europe, Moderna is expected to begin working with individual EU member states on procurement and rollout schedules ahead of the next respiratory virus season.
Analysis
Why This Matters
- A single combination vaccine for flu and COVID-19 could meaningfully improve adult vaccination rates by reducing the number of separate shots required each year, with direct public health benefits — particularly for elderly and immunocompromised populations.
- The European approval ahead of the US highlights a potentially widening gap in regulatory pace and vaccine policy priorities between the two regions, raising questions about the current state of US health agency decision-making.
- For Moderna, commercial success in Europe could bolster the financial case for continued mRNA platform investment and help offset declining COVID-only vaccine revenues.
Background
Moderna rose to global prominence with its COVID-19 mRNA vaccine, one of the first authorized during the pandemic. Following that success, the company invested heavily in expanding its mRNA pipeline to cover a range of infectious diseases, including influenza, respiratory syncytial virus (RSV), and combination products.
mRNA vaccine technology works by delivering genetic instructions that prompt cells to produce a protein mimicking part of a pathogen, triggering an immune response. Its flexibility makes it relatively straightforward to encode antigens from multiple pathogens in a single formulation — a key advantage over traditional vaccine manufacturing methods.
The concept of combination vaccines is not new — the MMR (measles, mumps, rubella) shot has been a childhood staple for decades — but combining annual respiratory vaccines targeting rapidly mutating viruses like flu and COVID-19 presents additional scientific and regulatory complexity. The EMA's positive committee review in February 2026 signaled confidence that the data submitted by Moderna demonstrated sufficient safety and efficacy for both components.
Key Perspectives
Moderna: The company frames mCOMBRIAX as a practical simplification of adult immunization, arguing that a single annual shot will reduce barriers to vaccination and ease pressure on healthcare systems. The European approval validates its mRNA platform strategy beyond COVID-19.
European Regulators: The EMA's scientific committee concluded that the benefit-risk profile of mCOMBRIAX is favorable, paving the way for the Commission's authorization. The EU has generally moved in step with scientific consensus on vaccine approvals in recent years.
Critics and Observers: Some public health analysts note that combination vaccines, while convenient, depend on both components being matched correctly to circulating strains each season — a particular challenge for influenza, which mutates rapidly. Others point to the absence of US FDA approval as a point of concern, though the reasons for the delay have not been fully explained publicly. In the current US political environment, skepticism toward vaccines and changes at federal health agencies have created uncertainty around the regulatory pathway for new vaccine products.
What to Watch
- Whether and when Moderna files or advances an FDA authorization application for mCOMBRIAX in the United States, and any public statements from the FDA regarding its review timeline.
- Procurement negotiations between Moderna and EU member states, which will determine how broadly and quickly the vaccine is deployed ahead of the 2026–27 respiratory season.
- Early real-world uptake data from Europe, which could provide evidence on whether combination dosing genuinely improves adult vaccination rates — a key metric for global health policymakers.